Limits...
Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis.

Eyawo O, Nachega J, Lefebvre P, Meyer D, Rachlis B, Lee CW, Kelly S, Mills E - Clin Ophthalmol (2009)

Bottom Line: First-line therapy for primary open-angle glaucoma and ocular hypertension generally involves prostaglandin analogue therapy.The relative efficacy of differing prostaglandin therapy is disputed.Travoprost was associated with greater incidence of conjunctival hyperemia than latanoprost (RR 5.71, 95% CI, 1.81 to 18.02, P </= 0.001, I2 = 97%, 95% CI, 95 to 98, P </= 0.001).

View Article: PubMed Central - PubMed

Affiliation: Faculty of Health Sciences, Simon Fraser University, Vancouver, Canada.

ABSTRACT

Background: First-line therapy for primary open-angle glaucoma and ocular hypertension generally involves prostaglandin analogue therapy. The relative efficacy of differing prostaglandin therapy is disputed.

Methods: A meta-analysis was conducted of head-to-head randomized trials of prostaglandin therapies. We included randomized trials assessing head-to-head evaluations of prostaglandin analogues travoprost, latanoprost and bimatoprost in patients with predominantly primary open-angle glaucoma or ocular hypertension. Findings were interpreted in light of equivalence margins.

Results: Our search identified 16 eligible trials, of which 15 were included in the meta-analysis. Trials were, in general, poorly reported. We pooled 9 trials assessing IOP-lowering effects of travoprost vs latanoprost (total n = 1098, weighted mean difference [WMD], -0.24 mmHg, 95% CI, -0.87 to 0.38, P = 0.45, I2 = 56%, 95% CI, 0 to 0.77, heterogeneity P = 0.01). Eight trials assessed travoprost vs bimatoprost (total n = 714, WMD, 0.88 mmHg, 95% CI, 0.13 to 1.63, P = 0.02, I2 = 56%, 95% CI, 0% to 78%, heterogeneity P = 0.02). And 8 trials assessed latanoprost vs bimatoprost (total n = 943, WMD, 0.73 mmHg, 95% CI, 0.10 to 1.37, P = 0.02, I2 = 47%, 95% CI, 0% to 74%, heterogeneity P = 0.06). Travoprost was associated with greater incidence of conjunctival hyperemia than latanoprost (RR 5.71, 95% CI, 1.81 to 18.02, P

Conclusion: Randomized head-to-head evaluations of prostaglandin therapy demonstrate similar efficacy effects, but differing hyperemia effects.

No MeSH data available.


Related in: MedlinePlus

Meta-analysis of latanoprost versus bimatoprost for IOP-lowering effects.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2724035&req=5

f4-opth-3-447: Meta-analysis of latanoprost versus bimatoprost for IOP-lowering effects.

Mentions: Table 3 presents IOP-lowering effects at the study conclusion for all included trials. We pooled 9 trials assessing travoprost to latanoprost (total n = 1098, Figure 2). The weighted mean difference across groups is −0.24 mmHg (95% CI, −0.87 to 0.38, P = 0.45, I2 = 56%, 95% CI, 0 to 0.77, heterogeneity P = 0.01). When we pooled 8 trials assessing travoprost to bimatoprost (total n = 688, Figure 3), we found a pooled weighted mean difference of 0.88 mmHg, 95% CI, 0.13 to 1.63, P = 0.02, I2 = 56%, 95% CI, 0 to 78). Finally, we pooled 8 trials assessing latanoprost with bimatoprost (total n = 974, Figure 4), we found a pooled weighted mean difference of 0.73 mmHg (95% CI, 0.10 to 1.37, P = 0.02, I2 = 47%, 95% CI, 0 to 74, heterogeneity P = 0.06). Study duration was not associated with therapeutic effects (B coefficient −0.21, 95% CI, −0.33 to 1.09).


Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis.

Eyawo O, Nachega J, Lefebvre P, Meyer D, Rachlis B, Lee CW, Kelly S, Mills E - Clin Ophthalmol (2009)

Meta-analysis of latanoprost versus bimatoprost for IOP-lowering effects.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2724035&req=5

f4-opth-3-447: Meta-analysis of latanoprost versus bimatoprost for IOP-lowering effects.
Mentions: Table 3 presents IOP-lowering effects at the study conclusion for all included trials. We pooled 9 trials assessing travoprost to latanoprost (total n = 1098, Figure 2). The weighted mean difference across groups is −0.24 mmHg (95% CI, −0.87 to 0.38, P = 0.45, I2 = 56%, 95% CI, 0 to 0.77, heterogeneity P = 0.01). When we pooled 8 trials assessing travoprost to bimatoprost (total n = 688, Figure 3), we found a pooled weighted mean difference of 0.88 mmHg, 95% CI, 0.13 to 1.63, P = 0.02, I2 = 56%, 95% CI, 0 to 78). Finally, we pooled 8 trials assessing latanoprost with bimatoprost (total n = 974, Figure 4), we found a pooled weighted mean difference of 0.73 mmHg (95% CI, 0.10 to 1.37, P = 0.02, I2 = 47%, 95% CI, 0 to 74, heterogeneity P = 0.06). Study duration was not associated with therapeutic effects (B coefficient −0.21, 95% CI, −0.33 to 1.09).

Bottom Line: First-line therapy for primary open-angle glaucoma and ocular hypertension generally involves prostaglandin analogue therapy.The relative efficacy of differing prostaglandin therapy is disputed.Travoprost was associated with greater incidence of conjunctival hyperemia than latanoprost (RR 5.71, 95% CI, 1.81 to 18.02, P </= 0.001, I2 = 97%, 95% CI, 95 to 98, P </= 0.001).

View Article: PubMed Central - PubMed

Affiliation: Faculty of Health Sciences, Simon Fraser University, Vancouver, Canada.

ABSTRACT

Background: First-line therapy for primary open-angle glaucoma and ocular hypertension generally involves prostaglandin analogue therapy. The relative efficacy of differing prostaglandin therapy is disputed.

Methods: A meta-analysis was conducted of head-to-head randomized trials of prostaglandin therapies. We included randomized trials assessing head-to-head evaluations of prostaglandin analogues travoprost, latanoprost and bimatoprost in patients with predominantly primary open-angle glaucoma or ocular hypertension. Findings were interpreted in light of equivalence margins.

Results: Our search identified 16 eligible trials, of which 15 were included in the meta-analysis. Trials were, in general, poorly reported. We pooled 9 trials assessing IOP-lowering effects of travoprost vs latanoprost (total n = 1098, weighted mean difference [WMD], -0.24 mmHg, 95% CI, -0.87 to 0.38, P = 0.45, I2 = 56%, 95% CI, 0 to 0.77, heterogeneity P = 0.01). Eight trials assessed travoprost vs bimatoprost (total n = 714, WMD, 0.88 mmHg, 95% CI, 0.13 to 1.63, P = 0.02, I2 = 56%, 95% CI, 0% to 78%, heterogeneity P = 0.02). And 8 trials assessed latanoprost vs bimatoprost (total n = 943, WMD, 0.73 mmHg, 95% CI, 0.10 to 1.37, P = 0.02, I2 = 47%, 95% CI, 0% to 74%, heterogeneity P = 0.06). Travoprost was associated with greater incidence of conjunctival hyperemia than latanoprost (RR 5.71, 95% CI, 1.81 to 18.02, P

Conclusion: Randomized head-to-head evaluations of prostaglandin therapy demonstrate similar efficacy effects, but differing hyperemia effects.

No MeSH data available.


Related in: MedlinePlus